All Journal articles – Page 7
-
-
JournalDoes sole dependence on reliance models contribute to a sustainable healthcare ecosystem?
Governments should strive for a sustainable and global regulatory framework adept to deal with a healthcare crisis and similar issues that may arise in the future. This article looks at regulatory frameworks in international regions through AstraZeneca’s experience with the VaxzevriaTM vaccine.
-
JournalThe transition period of the new API framework in Brazil is coming to an end
The new active pharmaceutical ingredients regulatory framework in Brazil begins August 2023
-
JournalRegistration and post-approval variation of pharmaceutical drugs in Latin America:
challenges and opportunitiesThis article provides an overview of the critical challenges for pharmaceutical drug registration and post-approval changes for manufacturers in six major Latin American countries.
-
JournalContraceptive product registration:
regional harmonisation through the East African Community mechanismThe COVID-19 pandemic disrupted access to contraception as a result of supply chain challenges, staff shortages and lockdowns, to name a few. This article looks at Catalyst Global’s experience in registering the contraceptive product, AVIBELA, using the East African Community Medicines Regulatory Harmonisation Initiative.
-
JournalAn overview of the regulatory framework for advanced therapies
Advanced therapy medicinal products (ATMPs) have recently advanced in development and are subject to regulation in some markets. This article summarises the regulatory framework for ATMPs in some of the markets where these requirements are in place: Argentina, Brazil, Europe, and the US.
-
-
-
JournalDirect healthcare professional communication as an intervention tool – retrospective analysis
The direct healthcare professional communication (DHPC) is a communication intervention by which important safety information is delivered directly to individual healthcare professionals (HCPs), alerting them to take certain actions to ensure the safe and effective use of medicines.
-
JournalIs consulting in regulatory affairs your next career path?
Navigating the corporate ladder isn’t always clear cut. Along the way you may move in and out of the industry, stay in one position for too long, or even jump from specialist to director. Some ditch the politics all together and become their own boss. What is it like being a consultant, contingent worker, or contractor?
-
JournalEMA’s IDMP-SPOR Implementation Guideline v2.1.1
Identification of Medicinal Products (IDMP) standards were developed by the ISO to specify the use of standardised definitions for the identification and description of medicinal products for human use. In this article, we provide an overview of the latest IDMP v2.1.1 guideline and summarise that, given the scope of changes, it is relatively low impact to the regulatory profession.
-
JournalEnvironmental impact of pharmaceuticals and regulation in the EU
The profound impact of pharmaceuticals on the environment has been acknowledged for decades. In the EU, two key mechanisms that assess this risk are the Environmental Risk Assessment (ERA), and Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). As both frameworks are under assessment, this article looks at the key considerations within the ERA.
-
JournalIMDRF: Origins, purpose and current work
In a landscape of rapidly evolving technologies, the International Medical Device Regulatory Forum (IMDRF) aims to accelerate international medical device harmonisation. A summary of the work being undertaken by the IMDRF.
-
-
JournalAccelerated regulatory pathways: Vaccines for tropical diseases
Reproduced from an online seminar presentation, made in collaboration with TOPRA and hVIVO, given on 21 June 2022 by Bruno Speder from hVIVO.
-
JournalRegulation versus innovation in life sciences
With Regulations evolving to meet the needs of changing technologies, demographics and health care practices, regulatory affairs professionals must ensure that the ever-changing requirements placed upon product or manufacturers are met and where possible met at minimal costs. Within this article we look to find innovative approaches to meet the different priorities which aim to reduce economic industry burden and ensure product availability.
-
JournalIVDs and medical devices — post-market surveillance and clinical follow-up requirements
Written by Kirsten Van Garsse from Qarad (part of the QbD Group) based on an online seminar presentation, made in collaboration with TOPRA and QbD, given on 6 December 2022 by Kirsten Van Garsse and Anne-Sophie Grell from QbD.
-
JournalPatient information — why do things go wrong?
Are common root causes leading to the pharmaceutical industry being non-compliant with the legal obligation to keep authorised product information up to date?
-
JournalA View of…The Environmental Impact of Pharmaceuticals
The body of research being published which is focused on the environmental impact of pharmaceuticals is increasing rapidly. It highlights a growing concern among the public for medicinal products accumulating in the natural world through a variety of originating sources.
-
JournalQuality management systems — applying good distribution practices to the biopharmaceutical supply chain
Biopharmaceutical supply chain strategies and alignment with good distribution practices (GDPs) are often viewed and planned with a focus on the post-marketing stage. Although this approach is valid, GDP compliance and supply chain strategies have important implications even during the clinical phases of product development. GDP regulations ensure that the integrity of medicinal products is maintained throughout all stages of the supply chain, from the manufacturer’s site to the pharmacy, or person authorised to supply to the public.